42 Chapter 2 Table 4: Summary outcomes in HIV-positive patients receiving TB treatment First author (Year/ Country) Study population Sample size % Hiv positive Outcome based on HIV status Tarbasi, P (2014 / Iran) New TB patients 158 3.2 Not assessed. Akinlade, K.S (2016 / Nigeria) MDR-TB patients 21 26.3 No difference in baseline HbA1c between HIVpositive and negative participants (p=0.954). Boillat-Blanco, N (2016 / Tanzania) Pulmonary TB patients 530 32 Using HbA1c, HIV-positive participants had lower odds of DM (p=0.048). No difference between those receiving ART and those not receiving ART. Lin, Y (2017 / China) TB Patients 270 3.3 Only 9/151 with known HIV status were HIV positive and 6/9 HIV positive patients had unstable FBG. HIV-positive participants had higher odds of unstable FBG after adjusting for confounding (p=0.027). Moreira, J (2018 / Brazil) HIV-TB coinfected patients 473 100 Successful treatment outcome - euglycaemic group (75%), hyperglycaemia group (28%), DM group (80%); Adverse event - euglycaemic group (25%), hyperglycaemia group (71%), DM group (20%); Death - euglycaemic group (7.5%), hyperglycaemia group (51%), DM group (10%); Lost to follow-up - euglycaemic group (17%), hyperglycaemia group (20%), DM group (10%). Diarra, B (2019 / Mali) TB patients 201 6.5 No HIV-positive participant developed DM during TB treatment. Kubjane, M (2020 / South Africa) Patients with respiratory symptoms 850 61 Significant positive association between DM and TB at baseline (OR, 2.4 [95% CI, 1.3–4.3]) and follow-up (OR, 3.3 [95% CI, 1.5–7.3]) regardless of HIV status.
RkJQdWJsaXNoZXIy MTk4NDMw